AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI-2620 for Alzheimer’s Disease
AC Immune Partner Life Molecular Imaging Initiates Phase 3 Study of Tau PET Diagnostic PI–2620 for Alzheimer’s Disease
Related news for (ACIU)
- AC Immune and Takeda Sign Exclusive Option and License Agreement Valued up to $2.1B
- AC Immune to Regain Global Rights to Crenezumab and Semorinemab
- AC Immune Progress Update on Phase 2 Active Immunotherapy Clinical Pipeline for Alzheimer’s and Parkinson diseases
- AC Immune Announces Pricing of Underwritten Offering of Common Shares
- AC Immune to Host Key Opinion Leader Webinar on Early Diagnosis and Prevention of Alzheimer’s Disease